PoxelFRA:7PO -0.73%37 Days Payable is 110.31 as of Jun. 2025, which is 90% below its 10-year median of 1,088.68. GuruFocus rates FRA:7PO with a GF Score™ of 37/100 and a GF Value™ of €1.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 704 Biotechnology companies, Poxel ranks better than 57.1% on this metric.
Poxel's average Accounts Payable for the
six
months ended in Jun. 2025 was €1.13 Mil. Poxel's Cost of Goods Sold for the
six
months ended in Jun. 2025 was €1.88 Mil.
Hence, Poxel's Days Payable for the
six
months ended in Jun. 2025 was 110.31.
The historical rank and industry rank for Poxel's Days Payable or its related term are showing as below:
FRA:7PO'
s Days Payable Range Over the Past 10 Years
Min: 102.51 Med: 1088.68 Max: 21195.17
Current: 151.74
During the past 13 years, Poxel's highest Days Payable was 21195.17. The lowest was 102.51. And the median was 1088.68.
FRA:7PO's Days Payable is ranked better than 57.1% of 704
companies
in the Biotechnology industry
Industry Median: 113.56
vs FRA:7PO: 151.74
Poxel's Days Payable
declined
from Jun. 2024 (280.68) to Jun. 2025 (110.31).
It may suggest that Poxelaccelerated paying its suppliers.
Poxel Days Payable Related Terms
Poxel Days Payable Historical Data
* Premium members only.
The historical data trend for Poxel's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7PO vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Poxel's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poxel Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poxel's Days Payable distribution charts can be found below:
* The bar in red indicates where Poxel's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Poxel's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poxel (FRA:7PO) has a Days Payable of 110.31 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Poxel and its competitors. This is 90% below median its historical median of 1,088.68. Over the past decade, Poxel's Days Payable has ranged from 102.51 to 21,195.17. According to the industry distribution chart, Poxel ranks #302 out of 704 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Poxel's Days Payable too high?
Poxel's current Days Payable of 110.31 is 90% below median its 10-year median of 1,088.68. Over the past 10 years, this metric has ranged from a low of 102.51 to a high of 21,195.17. The Biotechnology industry median Days Payable is 113.56. Poxel's value of 110.31 is 2.9% below this industry median. Based on the distribution chart, Poxel ranks #302 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Poxel has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Poxel's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poxel ranks #302 out of 704 companies for Days Payable. This puts Poxel in the upper half of its industry. The industry median Days Payable is 113.56. Poxel's value of 110.31 is 2.9% below this benchmark. Historically, Poxel's own Days Payable has ranged from 102.51 to 21,195.17 over the past decade. While the company's 10-year median is 1,088.68 vs. the industry median of 113.56, Poxel has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poxel's current Days Payable of 110.31 is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Poxel and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poxel's current Days Payable is 110.31, which is 90% below median its own 10-year median of 1,088.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poxel stock overvalued right now?
Based on GuruFocus' analysis, Poxel (FRA:7PO) is currently considered Possible Value Trap. The stock's GF Value™ is €1.15, compared to a current price of €0.20 — trading 82.3% below its estimated fair value. The current Days Payable is 110.31, which is 90% below median its 10-year median of 1,088.68 and 2.9% below the Biotechnology industry median of 113.56. Poxel's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Poxel (FRA:7PO), the current Days Payable is 110.31 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poxel (FRA:7PO) Overvalued in 2026?
Based on GuruFocus' analysis, Poxel stock appears to be undervalued.
The current stock price of €0.20 is trading 82.3% below its estimated GF Value™ of €1.15.
GuruFocus considers Poxel to be Possible Value Trap.
Key valuation signals for FRA:7PO:
Days Payable: 110.31 (90% below median its 10-year median of 1,088.68)
GF Value™: €1.15 vs. price of €0.20 (82.3% below fair value)
Industry Position: 2.9% below the Biotechnology median (#302 of 704)
No single metric tells the full story. See the FRA:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
37GF Score
Get the complete analysis for FRA:7PO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7PO has been successfully added to your 
